TABLE 3.
Relationship between preservation solutions and clinicopathological features of recipients.
| Total n = 380 | UW n = 267 | CS n = 83 | HTK n = 7 | IGL-1 n = 23 | P | |
| Age (years) | 40 (35–45) | 39 (34–44) | 42 (37–47) | 45 (33–49) | 47 (37–53) | 0.003a |
| 0.218b | ||||||
| 0.001c | ||||||
| Gender M/F | 240 (63.2)/140 (36.8) | 170 (63.7)/97 (36.3) | 55 (66.3)/28 (33.7) | 3 (42.9)/4 (57.1) | 12 (52.2)/11 (47.8) | 0.369a |
| 0.231b | ||||||
| 0.696c | ||||||
| BMI (kg/m2) | 22.7 (20.9–25.6) | 22.4 (20.6–25.5) | 23 (20.7–25.7) | 22.5 (21.2–26.1) | 23.1 (21.8–25.5) | 0.198a |
| 0.581b | ||||||
| 0.402c | ||||||
| DM type | <0.001a | |||||
| -DM I | 374 (98.4) | 266 (99.6) | 80 (96.4) | 7 (100) | 21 (91.3) | 0.017b |
| -Others | 6 (1.6) | 1 (0.4) | 3 (3.6) | 2 (8.7) | 0.015c | |
| DM vintage (years) | 26 (21–31) | 25 (21–30) | 28 (22–33.2) | 32 (25–34) | 27 (21–37) | 0.182a |
| 0.904b | ||||||
| 0.020c | ||||||
| Dialysis vintage (months) | 26.5 (17.4–36.7) | 26 (18–36.7) | 26.8 (19–36.1) | 47.3 (26.4–52.3) | 24 (11.5–35.3) | 0.361a |
| 0.322b | ||||||
| 0.917c | ||||||
| Type of dialysis | ||||||
| -Hemodialysis | 213 (56) | 151 (56.6) | 36 (43.4) | 5 (71.4) | 12 (52.2) | 0.846a |
| -Peritoneal dialysis | 85 (22.4) | 63 (23.6) | 22 (26.5) | 2 (28.6) | 5 (21.7) | 0.992b |
| -Pre-emptive | 30 (7.9) | 20 (7.5) | 9 (10.8) | 2 (8.7) | 0.469c | |
| -No dialysis | 52 (13.7) | 33 (12.3) | 9 (10.8) | 4 (17.4) | ||
| Transplant type | ||||||
| -SPK | 312 (82.1) | 224 (83.9) | 62 (74.7) | 7 (100) | 19 (82.6) | 0.933a |
| -PAK | 27 (7.1) | 16 (6) | 9 (10.8) | — | 2 (8.7) | 0.847b |
| -PA | 3 (0.8) | 2 (0.7) | 1 (1.2) | — | — | 0.281c |
| -Retransplant | 38 (10) | 25 (9.4) | 11 (13.3) | — | 2 (8.7) | |
| Induction therapy | ||||||
| -Basiliximab | 151 (39.7) | 116 (43.5) | 32 (38.5) | 3 (42.8) | - | <0.001a,b |
| -Thymoglobulin | 192 (50.5) | 114 (42.7) | 51 (61.5) | 4 (47.2) | 23 (100) | 0.001c |
| -Others | 37 (9.8) | 37 (13.8) | — | — | — | |
| Graft reconstruction | ||||||
| -SA-SMA | 350 (92.1) | 249 (93.3) | 72 (86.7) | 7 (100) | 22 (95.7) | 0.823a |
| -“Y” iliac graft | 27 (7.1) | 15 (5.6) | 11 (13.3) | — | 1 (4.3) | 0.191b |
| -Others | 3 (0.8) | 3 (1.1) | — | — | — | 0.012c |
| Intestinal anastomosis | — | — | — | — | — | |
| -Duodeno-jejunostomy | 337 (88.7) | 256 (95.9) | 67 (80.7) | 7 (100) | 7 (30.4) | <0.001a,b,c |
| -Duodeno-duodenostomy | 43 (11.3) | 11 (4.1) | 16 (19.3) | — | 16 (69.6) | |
| Transplant Era | ||||||
| -2000–2009 | 226 (59.5) | 220 (82.4) | 6 (7.2) | — | — | <0.001a,c |
| -2010–2019 | 154 (40.5) | 47 (117.6) | 77 (92.7) | 7 (100) | 23 (100) | 0.336b |
Continuous variables are expressed as median (interquartile ranges) and categorical variables as frequencies (percentages).
Comparison of the analysed variables have been made between UW, CS, and IGL-1, groups. For HTK, group only a descriptive analysis is displayed.
aIGL-1, vs. UW; bIGL-1, vs. CS; cUW, vs. CS.
M, indicates male; F, female; BMI, body mass index; DM, Diabetes Mellitus; SPK, Simultaneous Pancreas-Kidney; PAK, Pancreas After Kidney; PA, Pancreas Transplant Alone; SA-SMA, Splenic Artery - Superior Mesenteric Artery; UW, University of Wisconsin; CS, Celsior; HTK, Histidine-Tryptophan-Ketoglutarate; IGL-1, Institut Georges Lopez-1.